Table 2 EULAR (CRP) response rate and SDAI, CDAI, DAS28 (CRP), and Boolean remission rates up to week 24 (ITT population)
CT-P17 (N = 324) | EU-adalimumab (N = 324) | |
|---|---|---|
EULAR (CRP) response, n (%) | ||
Week 2 | ||
Good response | 22 (6.8) | 13 (4.0) |
Moderate response | 154 (47.5) | 139 (42.9) |
Week 4 | ||
Good response | 72 (22.2) | 68 (21.0) |
Moderate response | 162 (50.0) | 167 (51.5) |
Week 8 | ||
Good response | 133 (41.0) | 123 (38.0) |
Moderate response | 143 (44.1) | 144 (44.4) |
Week 12 | ||
Good response | 162 (50.0) | 165 (50.9) |
Moderate response | 131 (40.4) | 124 (38.3) |
Week 16 | ||
Good response | 181 (55.9) | 174 (53.7) |
Moderate response | 112 (34.6) | 109 (33.6) |
Week 20 | ||
Good response | 202 (62.3) | 201 (62.0) |
Moderate response | 91 (28.1) | 87 (26.9) |
Week 24 | ||
Good response | 208 (64.2) | 208 (64.2) |
Moderate response | 86 (26.5) | 81 (25.0) |
CDAI remission rate, n (%) | ||
Week 2 | 2 (0.6) | 2 (0.6) |
Week 4 | 11 (3.4) | 11 (3.4) |
Week 8 | 21 (6.5) | 24 (7.4) |
Week 12 | 47 (14.5) | 42 (13.0) |
Week 16 | 51 (15.7) | 63 (19.4) |
Week 20 | 69 (21.3) | 85 (26.2) |
Week 24 | 82 (25.3) | 86 (26.5) |
SDAI remission rate, n (%) | ||
Week 2 | 2 (0.6) | 2 (0.6) |
Week 4 | 12 (3.7) | 12 (3.7) |
Week 8 | 22 (6.8) | 22 (6.8) |
Week 12 | 47 (14.5) | 44 (13.6) |
Week 16 | 53 (16.4) | 65 (20.1) |
Week 20 | 69 (21.3) | 87 (26.9) |
Week 24 | 86 (26.5) | 93 (28.7) |
DAS28 (CRP) remission rate, n (%) | ||
Week 2 | 11 (3.4) | 10 (3.1) |
Week 4 | 32 (9.9) | 38 (11.7) |
Week 8 | 67 (20.7) | 68 (21.0) |
Week 12 | 109 (33.6) | 107 (33.0) |
Week 16 | 128 (39.5) | 118 (36.4) |
Week 20 | 150 (46.3) | 146 (45.1) |
Week 24 | 158 (48.8) | 157 (48.5) |
Boolean remission rate, n (%) | ||
Week 2 | 2 (0.6) | 2 (0.6) |
Week 4 | 9 (2.8) | 10 (3.1) |
Week 8 | 17 (5.2) | 17 (5.2) |
Week 12 | 32 (9.9) | 33 (10.2) |
Week 16 | 40 (12.3) | 56 (17.3) |
Week 20 | 56 (17.3) | 66 (20.4) |
Week 24 | 58 (17.9) | 68 (21.0) |